DK3909584T3 - Pyrimidinforbindelse eller salt deraf - Google Patents

Pyrimidinforbindelse eller salt deraf Download PDF

Info

Publication number
DK3909584T3
DK3909584T3 DK20737875.3T DK20737875T DK3909584T3 DK 3909584 T3 DK3909584 T3 DK 3909584T3 DK 20737875 T DK20737875 T DK 20737875T DK 3909584 T3 DK3909584 T3 DK 3909584T3
Authority
DK
Denmark
Prior art keywords
pyrimide
salt
compound
pyrimide compound
Prior art date
Application number
DK20737875.3T
Other languages
English (en)
Other versions
DK3909584T5 (da
Inventor
Masayuki Nakamura
Takahiro Asai
Satoru Iguchi
Kei Oguchi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3909584T3 publication Critical patent/DK3909584T3/da
Publication of DK3909584T5 publication Critical patent/DK3909584T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK20737875.3T 2019-01-11 2020-01-10 Pyrimidinforbindelse eller salt deraf DK3909584T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019003403 2019-01-11
PCT/JP2020/000592 WO2020145374A1 (ja) 2019-01-11 2020-01-10 ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
DK3909584T3 true DK3909584T3 (da) 2024-01-15
DK3909584T5 DK3909584T5 (da) 2024-08-05

Family

ID=71520288

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20737875.3T DK3909584T5 (da) 2019-01-11 2020-01-10 Pyrimidinforbindelse eller salt deraf

Country Status (20)

Country Link
US (1) US11078207B2 (da)
EP (1) EP3909584B1 (da)
JP (1) JP6783974B1 (da)
KR (1) KR102640463B1 (da)
CN (1) CN113271950B (da)
AU (1) AU2020206640B2 (da)
CA (1) CA3121722C (da)
DK (1) DK3909584T5 (da)
ES (1) ES2969151T3 (da)
FI (1) FI3909584T3 (da)
HU (1) HUE065967T2 (da)
MA (1) MA54702A (da)
MX (1) MX2021008252A (da)
MY (1) MY206124A (da)
PH (1) PH12021551630A1 (da)
PL (1) PL3909584T3 (da)
PT (1) PT3909584T (da)
SG (1) SG11202107528PA (da)
TW (1) TWI783204B (da)
WO (1) WO2020145374A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
US12492208B2 (en) 2020-07-15 2025-12-09 Taiho Pharmaceutical Co., Ltd. Crystal of pyrimidine compound
KR102873219B1 (ko) * 2020-07-15 2025-10-17 다이호야쿠힌고교 가부시키가이샤 Egfr 저해제
CA3199714A1 (en) * 2020-11-20 2022-05-27 Isao Miyazaki Brain-migrating tumor therapeutic agent containing fused pyrimidine compound as active ingredient
AU2022282261A1 (en) * 2021-05-24 2023-12-21 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2
WO2024173565A2 (en) * 2023-02-14 2024-08-22 New York University Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
MX360498B (es) * 2013-08-12 2018-11-05 Taiho Pharmaceutical Co Ltd Compuesto novedoso de pirimidina fusionada o sal del mismo.
KR102075886B1 (ko) 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
DK3269370T3 (da) 2016-02-23 2020-04-06 Taiho Pharmaceutical Co Ltd Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf
SG11201809223PA (en) 2016-04-19 2018-11-29 Univ California Erbb inhibitors and uses thereof
JP6779835B2 (ja) 2017-06-15 2020-11-04 株式会社日立製作所 監視制御システム、監視制御装置及び監視制御方法

Also Published As

Publication number Publication date
PL3909584T3 (pl) 2024-03-25
ES2969151T3 (es) 2024-05-16
EP3909584A1 (en) 2021-11-17
TWI783204B (zh) 2022-11-11
CN113271950B (zh) 2024-04-30
US11078207B2 (en) 2021-08-03
EP3909584A4 (en) 2022-09-28
EP3909584B1 (en) 2023-12-13
DK3909584T5 (da) 2024-08-05
MY206124A (en) 2024-11-30
CN113271950A (zh) 2021-08-17
TW202043230A (zh) 2020-12-01
KR102640463B1 (ko) 2024-02-23
MA54702A (fr) 2021-11-17
KR20210102373A (ko) 2021-08-19
WO2020145374A1 (ja) 2020-07-16
US20210024530A1 (en) 2021-01-28
AU2020206640B2 (en) 2022-09-08
AU2020206640A1 (en) 2021-08-12
PT3909584T (pt) 2024-01-12
SG11202107528PA (en) 2021-08-30
PH12021551630A1 (en) 2022-06-06
FI3909584T3 (fi) 2024-01-09
CA3121722A1 (en) 2020-07-16
JPWO2020145374A1 (ja) 2021-02-18
CA3121722C (en) 2024-01-16
MX2021008252A (es) 2021-08-16
BR112021013460A2 (pt) 2021-09-21
JP6783974B1 (ja) 2020-11-11
HUE065967T2 (hu) 2024-07-28

Similar Documents

Publication Publication Date Title
IL283692A (en) Novel composition
DK4083038T3 (da) Pyridazinylthiazolcarboxamidforbindelse
EP3578560A4 (en) QUINAZOLINE COMPOUND
DK3909584T5 (da) Pyrimidinforbindelse eller salt deraf
EP3928275A4 (en) MICROLOAN SYSTEM
DK3743337T3 (da) Vilkårlig kasselukker
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
EP3967649C0 (en) LIPID NANOPARTICLE
DK3808747T3 (da) Imidazopyridinon-forbindelse
EP4069093A4 (en) Bioprinting system
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3912517C0 (en) FRAME
EP3957391C0 (en) AGITATOR
EP3962498A4 (en) Combination therapies
EP3784015C0 (de) Anbaugerät
EP3979930C0 (en) MICRO-INTRODUCER SYSTEM
EP3965638C0 (en) VAGINAL SPECULUM
DK3738452T3 (da) Fordamper
DK3556683T3 (da) Fastgørelsesbånd
DK3764897T3 (da) Forbedret kapnometer
EP3669930C0 (en) OVERMOLDED SEPTUM
EP3682831C0 (en) CRYOGENIC APPLICATOR
PL3741550T3 (pl) Układ